Jennison Associates LLC Has $1.55 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Jennison Associates LLC increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 61.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,898 shares of the company’s stock after acquiring an additional 47,497 shares during the period. Jennison Associates LLC’s holdings in Amneal Pharmaceuticals were worth $1,552,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Rubric Capital Management LP grew its stake in Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 3.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock worth $70,681,000 after purchasing an additional 177,906 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Amneal Pharmaceuticals by 3.4% in the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock valued at $51,791,000 after buying an additional 136,662 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on AMRX shares. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays increased their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Finally, UBS Group raised their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $17.75 on Thursday. The firm has a market cap of $5.66 billion, a price-to-earnings ratio of 46.71 and a beta of 1.26. The business’s 50-day simple moving average is $15.36 and its 200-day simple moving average is $14.00. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.66 and a 52 week high of $18.39.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.